Compare Incyte Corporation (INCY) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Quanta Services Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Quanta Services Inc trades at $705.94 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 4.5× Incyte Corporation's market cap, and Quanta Services Inc pays a 0.06% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Quanta Services Inc for 62 Days on average.
| INCY | PWR | |
|---|---|---|
Market Cap | $22.85B | $103.03B |
Volume | 1,927,029 | 977,892 |
Sector | Health | Industrials |
52-Week High | $129.93 | $785.24 |
52-Week Low | $83.80 | $412.21 |
Typical Hold Time | 33 Days | 62 Days |
Enterprise Value | $18.35B | $109.13B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
PWR trades at $685.33, down 2.25% today but maintains strong technical momentum with bullish moving averages and support at $684. The company demonstrates robust fundamentals with revenue growth from $23.7B to $28.5B in 2025 and consistent earnings beats, while analyst sentiment remains overwhelmingly positive with 27 buy ratings and a $802.08 consensus target.
PWR offers compelling growth exposure to infrastructure and AI-driven data center demand, supported by a record $53B backlog and margin expansion potential. Key risks include execution challenges on large projects and sensitivity to economic cycles, but strong institutional support and positive earnings momentum suggest continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
